Veracyte, Inc. (NASDAQ:VCYT) is one of the 12 Best Genomics Stocks to Invest In, according to a recent report. Morgan Stanley has initiated coverage of VCYT with an Underweight rating and a price target of $48, up from $40.

VCYT has boosted its guidance for 2025, with total sales forecast now at $506 million to $510 million and testing revenue projections at $484 million to $487 million. Adjusted EBITDA margin is expected to be over 25%, with testing sales growth anticipated to be 16%.

Veracyte, Inc. (NASDAQ:VCYT) specializes in genomic diagnostics. While VCYT shows investment potential, other AI stocks may offer greater upside potential and less downside risk. For more information on undervalued AI stocks, check out the free report on the best short-term AI stock.

Disclosure: None.

Read more at Yahoo Finance: Morgan Stanley Initiates Coverage Of Veracyte, Inc. (VCYT)